Skip to main content

Table 4 Summary of dose to targets and OARs for all patients, shown as mean (standard deviation)

From: Evaluation of OAR dose sparing and plan robustness of beam-specific PTV in lung cancer IMRT treatment

Parameter General PTV optimization plan BSPTV optimization plan Pa
CTV, D98% (Gy) 61.68 (0.99) 61.40 (1.15) 0.280
General PTV, D98% (Gy) 60.00 (0.00) 58.84 (1.01) 0.001f
General PTV, D2% (Gy) 63.38 (1.35) 63.36 (1.53) 0.649
General PTV, CI 0.85 (0.05) 0.86 (0.05) 0.233
General PTV, HI 0.05 (0.02) 0.07 (0.03) 0.002f
BSPTV, D98% (Gy) 60.53 (0.50) 60.00 (0.00) 0.003f, 0.003c,f, 0.001d,f
BSPTV, D2% (Gy) 63.48 (1.41) 63.36 (1.51) 0.975
BSPTV, CI 0.79 (0.07) 0.84 (0.05) 0.003f, 0.281e
BSPTV, HI 0.05 (0.02) 0.05 (0.02) 0.100
Ring PTV, Dmean (Gy) 40.27 (6.83) 38.89 (7.13) 0.001f
Ring BSPTV, Dmean (Gy) 40.68 (6.72) 39.43 (7.08) 0.001f
Ring PTV, volume (cm3) 195.61 (203.99)   0.001b,f
Ring BSPTV, volume (cm3) 201.21 (210.89)   
Affected lung, V20 16.69 (11.32) 16.20 (10.85) 0.005f
Contralateral lung, V20 0.36 (0.01) 0.36 (0.01) 1.000
Total lungs, V20 7.25 (6.40) 7.02 (6.00) 0.008f
Affected lung, V5 29.22 (14.87) 28.75 (14.43) 0.013f
Contralateral lung, V5 6.91 (11.71) 6.71 (11.56) 0.028f
Total lungs, V5 16.26 (12.72) 15.92 (12.37) 0.015f
Affected lung, Dmean (Gy) 9.18 (5.51) 8.93 (5.28) 0.005f
Contralateral lung, Dmean (Gy) 0.97 (1.43) 0.95 (1.42) 0.012f
Total lungs, Dmean (Gy) 4.79 (3.33) 4.67 (3.18) 0.003f
Spinal cord, D1% (Gy) 16.14 (16.50) 15.72 (15.89) 0.009f
  1. HI homogeneity index, CI conformity index
  2. aComparison of general PTV optimization plan with BSPTV optimization plan
  3. bComparison of volumes of ring PTV and ring BSPTV
  4. cComparison of D98% of general PTV and BSPTV in the same general PTV optimization plan
  5. dComparison of D98% of general PTV and BSPTV in the same BSPTV optimization plan
  6. eComparison of CI of general PTV in the general PTV optimization plan and CI of BSPTV in the BSPTV optimization plan
  7. fP < 0.05